Bristol Myers Squibb has jettisoned another cancer candidate in-licensed under its former CEO. Immatics is the latest partner ...

Shares of Immatics (IMTX) have gained 1.2% over the past four weeks to close the last trading session at $12.52, but there could still be a solid upside left in the stock if short-term price ...

"ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific" was originally created and published by Clinical ...

Immatics (NASDAQ: IMTX), a clinical-stage biopharmaceutical company, maintained its Outperform rating and $16.00 price target from Mizuho. The affirmation follows recent developments including the ...

Bristol Myers Squibb is ending its collaboration with Immatics on IMA401, effective December 12, as part of portfolio ...

Bristol Myers Squibb presented the positive Phase III results on its already approved Opdivo-Yervoy combo at ESMO over the ...

“It is an exciting time for Immatics as we prepare to reach several major clinical milestones in the second half of the year. Starting with the presentation of the first clinical data on our TCR ...

Leerink Partners analyst Jonathan Chang maintained a Buy rating on Immatics (IMTX – Research Report) on September 8. The company’s ...

Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery ...

Immatics’ PRAME peptide is present at a high copy number per tumor cell and is homogeneously and specifically expressed in tumor tissue. The peptide has been identified and characterized by ...

Immatics (NASDAQ: IMTX), a clinical-stage biopharmaceutical company, maintained its Outperform rating and $16.00 price target from Mizuho. The affirmation follows recent developments including the ...